(ONC) BeiGene - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 30.408m USD | Total Return: 29.9% in 12m
Avg Turnover: 64.4M
Qual. Beats: 1
Rev. Trend: 99.4%
Qual. Beats: 1
Warnings
Altman Z'' -0.96 < 1.0 - financial distress zone
Choppy
Tailwinds
Confidence
BeOne Medicines AG, formerly known as BeiGene, Ltd., is a global oncology firm specializing in the discovery and commercialization of cancer therapeutics. The company maintains a diversified portfolio led by BRUKINSA, a BTK inhibitor for hematological malignancies, and TEVIMBRA, an anti-PD-1 immunotherapy. Its pipeline includes numerous clinical-stage candidates such as Bcl-2 inhibitors and chimeric degradation activation compounds (CDACs) targeting solid tumors and blood cancers.
The biotechnology sector relies heavily on long-term research and development cycles, where success often depends on securing strategic partnerships with major pharmaceutical entities like Amgen and Novartis. BeOne Medicines utilizes a global business model, operating across major markets in the United States, China, and Europe to maximize the reach of its specialized oncology treatments. For a more granular perspective on the companys fundamentals, consider reviewing the latest data on ValueRay.
- Brukinsa global market share expansion drives core oncology revenue growth
- Clinical trial results for Sonrotoclax determine next-generation hematology portfolio value
- Tevimbra regulatory approvals and reimbursement status impact solid tumor segment margins
- Geopolitical tensions and trade policies influence US-China manufacturing and R&D operations
- Strategic partnerships and royalty streams from Amgen and Novartis stabilize cash flow
| Net Income: 513.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 14.01 > 1.0 |
| NWC/Revenue: 83.46% < 20% (prev 45.81%; Δ 37.65% < -1%) |
| CFO/TA 0.15 > 3% & CFO 1.29b > Net Income 513.0m |
| Net Debt (-3.57b) to EBITDA (906.1m): -3.94 < 3 |
| Current Ratio: 3.64 > 1.5 & < 3 |
| Outstanding Shares: last quarter (115.8m) vs 12m ago 4.14% < -2% |
| Gross Margin: 88.31% > 18% (prev 0.85%; Δ 8.75k% > 0.5%) |
| Asset Turnover: 79.74% > 50% (prev 71.49%; Δ 8.25% > 0%) |
| Interest Coverage Ratio: 8.30 > 6 (EBITDA TTM 906.1m / Interest Expense TTM 91.1m) |
| A: 0.56 (Total Current Assets 6.60b - Total Current Liabilities 1.81b) / Total Assets 8.55b |
| B: -0.95 (Retained Earnings -8.09b / Total Assets 8.55b) |
| C: 0.11 (EBIT TTM 756.1m / Avg Total Assets 7.20b) |
| D: -2.15 (Book Value of Equity -8.15b / Total Liabilities 3.79b) |
| Altman-Z'' = -0.96 = CCC |
| DSRI: 0.93 (Receivables 948.4m/746.0m, Revenue 5.74b/4.18b) |
| GMI: 0.96 (GM 88.31% / 84.81%) |
| AQI: 0.61 (AQ_t 0.02 / AQ_t-1 0.03) |
| SGI: 1.37 (Revenue 5.74b / 4.18b) |
| TATA: -0.09 (NI 513.0m - CFO 1.29b) / TA 8.55b) |
| Beneish M = -3.18 (Cap -4..+1) = AA |
As of May 24, 2026, the stock is trading at USD 309.62 with a total of 235,218 shares traded.
Over the past week, the price has changed by +5.79%,
over one month by -0.69%,
over three months by -16.29% and
over the past year by +29.94%.
BeiGene has received a consensus analysts rating of 4.58. Therefore, it is recommended to buy ONC.
- StrongBuy: 15
- Buy: 8
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 411.4 | 32.9% |
P/E Forward = 47.619
P/S = 5.2984
P/B = 6.3898
Revenue TTM = 5.74b USD
EBIT TTM = 756.1m USD
EBITDA TTM = 906.1m USD
Long Term Debt = 962.5m USD (from longTermDebt, last quarter)
Short Term Debt = 136.7m USD (from shortTermDebt, last quarter)
Debt = 1.22b USD (from shortLongTermDebtTotal, last quarter) + Leases 70.3m
Net Debt = -3.57b USD (calculated: Debt 1.22b - CCE 4.79b)
Enterprise Value = 26.8b USD (30.4b + Debt 1.22b - CCE 4.79b)
Interest Coverage Ratio = 8.30 (Ebit TTM 756.1m / Interest Expense TTM 91.1m)
EV/FCF = 31.70x (Enterprise Value 26.8b / FCF TTM 846.5m)
FCF Yield = 3.15% (FCF TTM 846.5m / Enterprise Value 26.8b)
FCF Margin = 14.75% (FCF TTM 846.5m / Revenue TTM 5.74b)
Net Margin = 8.94% (Net Income TTM 513.0m / Revenue TTM 5.74b)
Gross Margin = 88.31% ((Revenue TTM 5.74b - Cost of Revenue TTM 670.8m) / Revenue TTM)
Gross Margin QoQ = 88.95% (prev 90.49%)
Tobins Q-Ratio = 3.14 (Enterprise Value 26.8b / Total Assets 8.55b)
Interest Expense / Debt = 7.47% (Interest Expense 91.1m / Debt 1.22b)
Taxrate = 12.29% (31.9m / 259.2m)
NOPAT = 663.2m (EBIT 756.1m * (1 - 12.29%))
Current Ratio = 3.64 (Total Current Assets 6.60b / Total Current Liabilities 1.81b)
Debt / Equity = 0.26 (Debt 1.22b / totalStockholderEquity, last quarter 4.76b)
Debt / EBITDA = -3.94 (Net Debt -3.57b / EBITDA 906.1m)
Debt / FCF = -4.22 (Net Debt -3.57b / FCF TTM 846.5m)
Total Stockholder Equity = 4.26b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.13% (Net Income 513.0m / Total Assets 8.55b)
RoE = 4.15% (Net Income TTM 513.0m / Total Stockholder Equity 12.3b)
RoCE = 5.68% (EBIT 756.1m / Capital Employed (Equity 12.3b + L.T.Debt 962.5m))
RoIC = 9.93% (NOPAT 663.2m / Invested Capital 6.68b)
WACC = 7.63% (E(30.4b)/V(31.6b) * Re(7.67%) + D(1.22b)/V(31.6b) * Rd(7.47%) * (1-Tc(0.12)))
Discount Rate = 7.67% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 94.39 | Cagr: 4.85%
[DCF] Terminal Value 75.44% ; FCFF base≈846.5m ; Y1≈850.0m ; Y5≈900.4m
[DCF] Fair Price = 185.2 (EV 14.0b - Net Debt -3.57b = Equity 17.6b / Shares 94.9m; r=8.35% [WACC [floored]]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.35 | # QB: 1
Revenue Correlation: 99.41 | Revenue CAGR: 50.29% | SUE: 1.65 | # QB: 1
EPS current Quarter (2026-06-30): EPS=1.55 | Chg30d=+16.85% | Revisions=+54% | Analysts=11
EPS next Quarter (2026-09-30): EPS=1.67 | Chg30d=+11.43% | Revisions=+9% | Analysts=11
EPS current Year (2026-12-31): EPS=6.56 | Chg30d=+18.77% | Revisions=+65% | GrowthEPS=+159.4% | GrowthRev=+21.1%
EPS next Year (2027-12-31): EPS=9.58 | Chg30d=+3.15% | Revisions=+22% | GrowthEPS=+46.0% | GrowthRev=+14.7%
[Analyst] Revisions Ratio: +65%